Analysis
As of November 22, 2026, Swiss specialty chemicals maker Clariant and US private equity firm CD&R are in talks to buy Ashland Inc. in an all-cash deal that would value the company at about $3.39 billion, Reuters reported, citing Bloomberg News. Bloomberg's report says the price would sit close to Ashland's Friday share price and that a deal could come together as soon as the coming days.
Nothing is signed. No final decision has been made, the talks could fall through and another suitor could still emerge, according to both reports. Ashland and Clariant declined to comment, and CD&R did not immediately respond. Until a merger agreement is announced, the $3.39 billion figure is a reported negotiating value, not a deal.
What does Ashland do?
Ashland is a Wilmington, Delaware-based maker of additives and specialty ingredients used in pharmaceuticals, construction and personal care products, per Bloomberg. Trade outlet Personal Care Insights describes it as a specialty cosmetic ingredient manufacturer that supplies personal care and other consumer markets. For fiscal 2025, Ashland reported $1.824 billion in sales, down 14% from fiscal 2024, according to MyChesCo's report on its annual results.
“Until a merger agreement is announced, the $3.39 billion figure is a reported negotiating value, not a deal.”
That shrinking top line is the context for the price. A company that lost 14% of its sales in a year and then ran a public sale process is now, by Bloomberg's account, negotiating at roughly what the stock market already paid for it.
How Ashland ended up for sale
The process has run for most of 2026:
- July 2026 -- Ashland put itself up for sale after settling with activist investor Ancora Holdings Group, in an agreement that called for two new board members (Bloomberg).
- August 2026 -- Ashland was working with Citigroup and Lazard on a potential sale, Bloomberg reported, and Personal Care Insights reported takeover interest from strategic buyers and private equity firms.
- October 2, 2026 -- Ashland collected initial bids, with shares at about $68.76 and a market capitalisation of about $3.14 billion, per Mergermarket's Activist Monitor.
- November 20, 2026 -- Ashland shares fell 2.3% to $72.40 in New York trading, leaving the stock up 23% this year and the company's market value at $3.3 billion, per Bloomberg.
- November 22, 2026 -- Bloomberg reports the Clariant and CD&R talks; Reuters, citing Bloomberg, gives a value of about $3.39 billion.
Value Add VC data
Ashland is a public company, so there are no venture rounds to list. These are the sale-process marks we could verify:
- Oct 2026, initial bids -- shares about $68.76, market cap about $3.14B (Mergermarket)
- Oct 2026, Ancora base case -- 11.5x estimated FY26 adjusted EBITDA, or $76.47 a share (Mergermarket)
- Nov 2026, last close before the report -- $72.40 a share, $3.3B market value (Bloomberg via Swissinfo)
- Nov 2026, reported deal value -- about $3.39B, all cash (Reuters)
The reported $3.39 billion is about 8% above the $3.14 billion market cap Mergermarket recorded at the October bid round.
The activist math cuts the other way. Ancora, which held a 4.24% stake per Mergermarket, put forward $76.47 a share as its base case. Neither report gives a per-share price, and neither says whether $3.39 billion is an equity or an enterprise value. As a rough Pulse desk estimate only: Bloomberg's $3.3 billion market value at Friday's $72.40 close implies about 45.6 million shares, so $3.39 billion of equity would work out to roughly $74 a share, about 3% above Friday's close and about 3% below Ancora's base case. If the price lands close to Friday's close, as Bloomberg's sources say, the activist that started the process would be taking somewhat less than its own opening number.
Two other takeovers on Pulse this week give the scale:
- Quotient Sciences -- IQVIA's reported $1.1B takeover move
- BILL -- a $6.0B take-private by TPG with Corpay
Who is buying Ashland, and who else bid?
Clariant is the Swiss specialty chemicals group in the talks; CD&R is Clayton, Dubilier & Rice, the US buyout firm. Mergermarket reported in October that CD&R had partnered with Clariant for the process. The same report named Advent International, Apollo and Carlyle as interested private equity firms and said Standard Industries was considering an approach. Personal Care Insights describes Standard Industries as already one of Ashland's biggest shareholders, and Reuters says Advent, Apollo, Carlyle and Standard Industries have all been in contact with Ashland. Our interpretation: a strategic buyer paired with a buyout fund suggests the two plan to divide Ashland's product lines between them, but neither party has said how the business would be split.
The risk in reading this as a done deal is that Bloomberg's sources put the price close to Friday's close, and the basis of the $3.39 billion figure (equity or enterprise value) is undisclosed, so no large premium is on the table in the reporting so far. However the talks end, three things decide the outcome: whether a signed agreement arrives in the coming days, as Bloomberg's sources expect; whether the price moves toward Ancora's $76.47 base case; and whether Advent, Apollo, Carlyle or Standard Industries returns with a higher offer before Clariant and CD&R sign.